Recursion Pharmaceuticals, Inc. (RXRX) NASDAQ
3.59
+0.15(+4.36%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Recursion Pharmaceuticals, Inc.
Address
41 South Rio Grande Street
Salt Lake City, UT 84101
United States of America (the)
Phone
385 269 0203
Website
Sector
Healthcare
Industry
Biotechnology
Employees
800
First IPO Date
April 16, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Najat Khan | CEO, President & Director | 903,460 | 1984 |
| Ben R. Taylor | Chief Financial Officer & President of Recursion UK | 751,492 | 1977 |
| Vicki L. Goodman | Chief Medical Officer | 793,399 | 1971 |
| David J. Mauro | Advisor | 793,399 | 1965 |
| Christopher C. Gibson | Co-Founder, Chairman & Interim Executive Advisor | 952,508 | 1983 |
| David Hallett | Chief Scientific Officer | 0 | 1969 |
| Elizabeth Bruckheimer | Vice President of Clinical Development | 0 | N/A |
| Matthew Kinn | Chief Business Officer | 0 | N/A |
| Nathan Hatfield | Chief Legal Officer & Corporate Secretary | 0 | N/A |
| Ryan Kelly | Chief Communications Officer | 0 | N/A |
| Sid Jain | Senior Vice President of Clinical Development & Data Science | 0 | N/A |
| Erica Fox | Chief People and Impact Officer | 0 | N/A |
| Kristen Rushton | Chief Operating Officer | 0 | N/A |
| Benjamin Mabey | Chief Technology Officer | 0 | 1983 |
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
